Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives
Steroidal compounds have emerged as effective therapeutic agents in oncology. Beyond natural-occurring and synthetic steroids that act as cytotoxic anti-tumoral agents, steroidal derivatives can be designed to mime the endogenous substrates of key metabolic enzymes in steroidogenesis, thus reducing...
Saved in:
| Main Authors: | Bruno Cerra, Antimo Gioiello |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2025.2483818 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STEROIDOGENESIS PATHWAY AND BREAST CANCER: EMPOWERING PERSONALIZED TREATMENT WITH A METABOLOMICS APPROACH
by: Mete Bora Tüzüner
Published: (2022-08-01) -
Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report
by: Jiaxi Deng, et al.
Published: (2024-11-01) -
Pyridine indole hybrids as novel potent CYP17A1 inhibitors
by: Tomasz M. Wróbel, et al.
Published: (2025-12-01) -
Nanoparticles with curcumin and piperine modulate steroid biosynthesis in prostate cancer
by: Jibira Yakubu, et al.
Published: (2025-04-01) -
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)